Scholarlink

<p><i>Acinetobacter baumannii</i> is a prevalent clinical pathogen commonly found to be multidrug-resistant (MDR), causing serious to life-threatening infections, particularly hospital-acquired infections with limited therapeutic options. The MDR phenotype developed against this critical pathogen is increasingly developed globally, reaching a pan-drug-resistant phenotype conferring non-susceptibility to all antimicrobials used in its treatment according to the standard guidelines. Therefore, it is critical to develop innovative treatment approaches, such as phage therapy, considering the rise in drug-resistant <i>A. baumannii</i> infections. In this review, we highlight and discuss the up-to-date antimicrobial resistance of <i>A. baumannii</i>, the use of phages, their limitations, and future perspectives in treating <i>A. baumannii</i> infections. In addition, the combination of phages with antimicrobials, preclinical and clinical studies including pharmacokinetics and pharmacodynamics properties have been discussed.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Recent insights on phage therapy against multidrug-resistant Acinetobacter baumannii

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月12日

查看全文
  • Ann A. Elshamy,
  • Sandra K. Kamal,
  • Mariam T. Mahmoud,
  • Aya M. Elhasany,
  • Aya A. Shady,
  • Sherok A. Mohamed,
  • Hasna A. Abd-Elmaaboud,
  • Nour E. El-Awady,
  • Rana A. Mohamed,
  • Sara A. El-Mirghany,
  • Sarraa W. El-Hady,
  • Mohamed M. Abd-ElRahman,
  • Khaled M. Aboshanab

摘要

Acinetobacter baumannii is a prevalent clinical pathogen commonly found to be multidrug-resistant (MDR), causing serious to life-threatening infections, particularly hospital-acquired infections with limited therapeutic options. The MDR phenotype developed against this critical pathogen is increasingly developed globally, reaching a pan-drug-resistant phenotype conferring non-susceptibility to all antimicrobials used in its treatment according to the standard guidelines. Therefore, it is critical to develop innovative treatment approaches, such as phage therapy, considering the rise in drug-resistant A. baumannii infections. In this review, we highlight and discuss the up-to-date antimicrobial resistance of A. baumannii, the use of phages, their limitations, and future perspectives in treating A. baumannii infections. In addition, the combination of phages with antimicrobials, preclinical and clinical studies including pharmacokinetics and pharmacodynamics properties have been discussed.